CHEK1 and colorectal carcinoma: Whilst the exact molecular signature for sensitivity to CHK1 inhibitor monotherapy is still under investigation, the findings of this study suggest that P53 status/functioning is a likely key factor in determining SRA737 efficacy in the NSCLC and CRC setting.